Vistra Corp
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
6. Earnings Per Share
- EARNINGS PER SHARE
Basic earnings per share available to common stockholders are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the treasury stock method and includes the effect of all potential issuances of common shares under stock-based incentive compensation arrangements.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| (in millions, except share data) | ||||
| Net income attributable to Vistra | $1,888 | $502 | $2,218 | $1,677 |
| Less cumulative dividends attributable to Series A Preferred Stock | (20) | (20) | (60) | (60) |
| Less cumulative dividends attributable to Series B Preferred Stock | (17) | (17) | (52) | (52) |
| Less cumulative dividends attributable to Series C Preferred Stock | (11) | — | (32) | — |
| Net income attributable to common stock — basic and diluted | 1,840 | 465 | $2,074 | $1,565 |
| Weighted average shares of common stock outstanding: | ||||
| Basic | 342,969,916 | 366,570,040 | 346,315,125 | 374,323,466 |
| Dilutive securities: Stock-based incentive compensation plan | 7,233,776 | 5,579,059 | 7,490,812 | 4,778,892 |
| Diluted | 350,203,692 | 372,149,099 | 353,805,937 | 379,102,358 |
| Net income per weighted average share of common stock outstanding: | ||||
| Basic | $5.36 | $1.27 | $5.99 | $4.18 |
| Diluted | $5.25 | $1.25 | $5.86 | $4.13 |
Stock-based incentive compensation plan awards excluded from the calculation of diluted earnings per share because the effect would have been antidilutive totaled 531 and 17,847 for the three months ended September 30, 2024 and 2023, respectively, and 11,210 and 1,491,299 shares for the nine months ended September 30, 2024 and 2023, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.